Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 360

2.

Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.

Haruta H, Ohguro N, Fujimoto M, Hohki S, Terabe F, Serada S, Nomura S, Nishida K, Kishimoto T, Naka T.

Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3264-71. doi: 10.1167/iovs.10-6272.

PMID:
21330657
3.

Differentiation of Th1 and Th2 cells in lymph nodes and spleens of mice during experimental autoimmune uveoretinitis.

Takeuchi M, Yokoi H, Tsukahara R, Sakai J, Usui M.

Jpn J Ophthalmol. 2001 Sep-Oct;45(5):463-9.

PMID:
11583666
4.

[Effects of leflunomide on experimental autoimmune uveitis in Lewis rats].

Fang C, Zhou D, Zhan S, He Y, Lin Z, Huang C, Li J.

Zhonghua Yan Ke Za Zhi. 2015 Oct;51(10):754-61. Chinese.

PMID:
26693771
5.

[Regulation of antigen specific Th17 cells differentiation in experimental autoimmune uveitis].

Chen HT, Wang H, Zhao M, Hou B.

Zhonghua Yan Ke Za Zhi. 2012 Mar;48(3):234-40. Chinese.

PMID:
22800421
6.

SLAT/Def6 plays a critical role in the pathogenic process of experimental autoimmune uveitis (EAU).

Vistica BP, Shi G, Nugent L, Tan C, Altman A, Gery I.

Mol Vis. 2012;18:1858-64. Epub 2012 Jul 7.

7.

Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis.

Keino H, Watanabe T, Sato Y, Niikura M, Wada Y, Okada AA.

Arthritis Res Ther. 2008;10(5):R122. doi: 10.1186/ar2530. Epub 2008 Oct 13.

9.

Regulation of interphotoreceptor retinoid-binding protein (IRBP)-specific Th1 and Th17 cells in anterior chamber-associated immune deviation (ACAID).

Cui Y, Shao H, Sun D, Kaplan HJ.

Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5811-7. doi: 10.1167/iovs.09-3389. Epub 2009 May 20.

10.
11.

IFN-β inhibits the increased expression of IL-9 during experimental autoimmune uveoretinitis.

Yang Y, Du L, Sun M, Kijlstra A, Yang P.

PLoS One. 2012;7(10):e48566. doi: 10.1371/journal.pone.0048566. Epub 2012 Oct 30.

12.

Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats.

Fang CB, Zhou DX, Zhan SX, He Y, Lin Z, Huang C, Li J.

PLoS One. 2013 Apr 23;8(4):e62071. doi: 10.1371/journal.pone.0062071. Print 2013.

13.

Invariant NKT cells regulate experimental autoimmune uveitis through inhibition of Th17 differentiation.

Oh K, Byoun OJ, Ham DI, Kim YS, Lee DS.

Eur J Immunol. 2011 Feb;41(2):392-402. doi: 10.1002/eji.201040569. Epub 2010 Dec 29.

14.

CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.

Iwahashi C, Fujimoto M, Nomura S, Serada S, Nakai K, Ohguro N, Nishida K, Naka T.

Exp Eye Res. 2015 Nov;140:53-64. doi: 10.1016/j.exer.2015.08.012. Epub 2015 Aug 20.

PMID:
26297802
15.

Regulatory effects of IFN-β on the development of experimental autoimmune uveoretinitis in B10RIII mice.

Sun M, Yang Y, Yang P, Lei B, Du L, Kijlstra A.

PLoS One. 2011 May 6;6(5):e19870. doi: 10.1371/journal.pone.0019870. Erratum in: PLoS One. 2011;6(10). doi:10.1371/annotation/5934536e-ca5d-4ee8-bd71-7cfdc2e6d36c.

16.

Pertussis toxin enhances Th1 responses by stimulation of dendritic cells.

Hou W, Wu Y, Sun S, Shi M, Sun Y, Yang C, Pei G, Gu Y, Zhong C, Sun B.

J Immunol. 2003 Feb 15;170(4):1728-36.

17.

IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.

Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan CC, Wiggert B, Caspi RR.

J Immunol. 1997 Jun 15;158(12):5997-6005.

PMID:
9190954
18.

Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category.

Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, Bowman EP, Sgambellone NM, Chan CC, Caspi RR.

J Exp Med. 2008 Apr 14;205(4):799-810. doi: 10.1084/jem.20071258. Epub 2008 Apr 7.

19.

Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.

Hohki S, Ohguro N, Haruta H, Nakai K, Terabe F, Serada S, Fujimoto M, Nomura S, Kawahata H, Kishimoto T, Naka T.

Exp Eye Res. 2010 Aug;91(2):162-70. doi: 10.1016/j.exer.2010.04.009. Epub 2010 Apr 24.

PMID:
20420831
20.

Leucine-Rich Repeat Kinase 2 (Lrrk2) Deficiency Diminishes the Development of Experimental Autoimmune Uveitis (EAU) and the Adaptive Immune Response.

Wandu WS, Tan C, Ogbeifun O, Vistica BP, Shi G, Hinshaw SJ, Xie C, Chen X, Klinman DM, Cai H, Gery I.

PLoS One. 2015 Jun 11;10(6):e0128906. doi: 10.1371/journal.pone.0128906. eCollection 2015.

Supplemental Content

Support Center